HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, A. K. Articles by Innis, R. B. Search for Related Content PubMed PubMed Citation Articles by Brown, A. K. Articles by Innis, R. B.

Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET

Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland

Correspondence: For correspondence or reprints contact: Robert B. Innis, Molecular Imaging Branch, National Institute of Mental Health, 31 Center Dr., Room B2/B37 Bethesda, MD 20892-2035. E-mail: robert.innis{at}nih.gov

We developed a radioligand, 3-fluoro-5-(2-(2-¹⁸F-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile (¹⁸F-SP203), for metabotropic glutamate subtype 5 (mGluR5) receptors that showed both promising (high specific binding) and problematic (defluorination) imaging characteristics in animals. The purposes of this initial evaluation in human subjects were to determine whether ¹⁸F-SP203 is defluorinated in vivo (as measured by uptake of radioactivity in the skull) and to determine whether the uptake in the brain can be quantified as distribution volume relative to concentrations of ¹⁸F-SP203 in plasma. Methods: Seven healthy subjects were injected with ¹⁸F-SP203 (323 ± 87 MBq) and scanned over 5 h, with rest periods outside the camera. The concentrations of ¹⁸F-SP203, separated from radiometabolites, were measured in arterial plasma. Results: The skull was difficult to visualize on PET images in the initial 2 h, because of high radioactivity in the brain. Although radioactivity in the skull and adjacent cortex showed some cross-contamination, the concentration of radioactivity in the skull was less than half of that in the adjacent cortex during the initial 2 h. Modeling of regional brain and plasma data showed that a 2-tissue-compartment model was superior to a 1-tissue-compartment model, consistent with measurable amounts of both receptor-specific and nonspecific binding. The concentrations of activity in the brain measured with PET were consistently greater than the modeled values at late but not early time points and may well have been caused by the slow accumulation of radiometabolites in the brain. To determine an adequate time for more accurate measurement of distribution volume, we selected a scan duration (i.e., 2 h) associated with maximal or near-maximal identifiability. Distribution volume was well identified (2%) by only 2 h (and even just 1) of image acquisition. Conclusion: This initial evaluation of ¹⁸F-SP203 in healthy human subjects showed that defluorination is relatively small and that brain uptake can be robustly calculated as distribution volume. The values of distribution volume were well identified and had relatively small variation in this group of 7 subjects. These results suggest that ¹⁸F-SP203 will have good sensitivity to measure mGluR5 receptors for both within-subject studies (e.g., receptor occupancy) and between-subject studies (e.g., patients vs. healthy subjects).

Key Words: molecular imaging • glutamate neurotransmission • PET

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				H. U. Shetty, S. S. Zoghbi, F. G. Simeon, J.-S. Liow, A. K. Brown, P. Kannan, R. B. Innis, and V. W. Pike Radiodefluorination of 3-Fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a Radioligand for Imaging Brain Metabotropic Glutamate Subtype-5 Receptors with Positron Emission Tomography, Occurs by Glutathionylation in Rat Brain J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 727 - 735. [Abstract] [Full Text] [PDF]